MAPT and Cognitive impairment: Dual GLP-1/GIP RA improved cognitive impairment in a range of tests and relieved the pathological features of APP/PS1/tau mice, enhanced long-term potentiation in the hippocampus, increased the number of synapses and dendritic spines, and normalized the volume and number of mitochondria while downregulating amyloids and phosphorylated tau protein [221].